Overall, high-risk MM patients—defined by specific molecular (p53 mutations) and cytogenetic (hypoploid or complicated karyotypes) risk markers—had higher T/Mmax (P < 0.01, Figure 3), and a higher incidence of extramedullary lesions (75.00% vs. 18.33%, P < 0.01). Here, TP53 is linked to Miyoshi myopathy.